Genmab A/S ADS stock is trading -25.59% below its average target price of $29.31 after marking a 4.1% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $20.0 to $45.0 per share.
The stock has a very low short interest at 0.4%, and a short ratio of 1.86. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 10.4% of Genmab A/S ADS's shares being owned by this investor type.
Institutions Invested in Genmab A/S ADS
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Alliancebernstein L.P. | 2% | 14,725,158 | $321,155,688 |
| 2025-03-31 | Orbis Allan Gray Ltd | 1% | 5,710,741 | $124,551,258 |
| 2025-03-31 | Citadel Advisors Llc | 1% | 4,426,654 | $96,545,321 |
| 2025-03-31 | Blackrock Inc. | 1% | 3,517,852 | $76,724,350 |
| 2025-03-31 | Harding Loevner LLC | 0% | 2,880,826 | $62,830,813 |
| 2025-03-31 | Morgan Stanley | 0% | 2,838,928 | $61,917,018 |
| 2025-03-31 | Renaissance Technologies, LLC | 0% | 2,262,350 | $49,341,852 |
| 2025-03-31 | Marshall Wace LLP | 0% | 2,181,510 | $47,578,731 |
| 2025-03-31 | Two Sigma Advisers, LP | 0% | 1,973,700 | $43,046,395 |
| 2025-03-31 | Two Sigma Investments, LP | 0% | 1,899,766 | $41,433,895 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Genmab A/S ADS.
